Enterocolitis - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Enterocolitis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Enterocolitis - Pipeline Review, H2 2015', provides an overview of the Enterocolitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Enterocolitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterocolitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Enterocolitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Enterocolitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Enterocolitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Enterocolitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Enterocolitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Enterocolitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Enterocolitis Overview 6
Therapeutics Development 7
Pipeline Products for Enterocolitis - Overview 7
Pipeline Products for Enterocolitis - Comparative Analysis 8
Enterocolitis - Therapeutics under Development by Companies 9
Enterocolitis - Therapeutics under Investigation by Universities/Institutes 10
Enterocolitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Enterocolitis - Products under Development by Companies 13
Enterocolitis - Products under Investigation by Universities/Institutes 14
Enterocolitis - Companies Involved in Therapeutics Development 15
Angothera GmbH 15
AvidBiotics Corp. 16
Infant Bacterial Therapeutics AB 17
Sigma-Tau Pharmaceuticals, Inc 18
Enterocolitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
Antibodies for Enterocolitis - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AvR2-V10 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
C-34 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IBP-9414 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NRG-4 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
STP-206 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Enterocolitis - Recent Pipeline Updates 37
Enterocolitis - Dormant Projects 38
Enterocolitis - Product Development Milestones 39
Featured News & Press Releases 39
Jun 24, 2015: BioGaia Subsidiary IBT Takes Rapid Steps in Development of a Drug for Premature Infants 39
Jun 12, 2015: BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics 39
Apr 01, 2015: Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation for STP-206 for Prevention of Necrotizing Enterocolitis 39
Mar 26, 2015: Infant Bacterial Therapeutics receives additional funding from mother company BioGaia 40
Feb 23, 2015: BioGaia subsidiary Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe 40
Feb 04, 2014: Sigma-Tau Pharmaceuticals Announces First Patient Dosed in Phase I/II Clinical Trial of STP206 for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Premature Infants 41
Apr 07, 2009: Sigma-Tau Partners With Danisco Bioactive To Develop Drug Candidate For Prevention Of Necrotizing Enterocolitis 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

Number of Products under Development for Enterocolitis, H2 2015 7
Number of Products under Development for Enterocolitis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Enterocolitis - Pipeline by Angothera GmbH, H2 2015 15
Enterocolitis - Pipeline by AvidBiotics Corp., H2 2015 16
Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2015 17
Enterocolitis - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 24
Number of Products by Stage and Molecule Type, H2 2015 26
Enterocolitis Therapeutics - Recent Pipeline Updates, H2 2015 37
Enterocolitis - Dormant Projects, H2 2015 38